Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Calithera Biosciences is a biotechnology business based in the US. Calithera Biosciences shares (CALA) are listed on the NASDAQ and all prices are listed in US Dollars. Calithera Biosciences employs 63 staff and has a market cap (total outstanding shares value) of 0.00.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $0.05 |
|---|---|
| 52-week range | $0.04 - $13.38 |
| 50-day moving average | $0.19 |
| 200-day moving average | $2.18 |
| Wall St. target price | $5.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-20.48 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.05 from 2023-03-27
| 1 week (2023-03-22) | 2.67% |
|---|---|
| 1 month (2023-03-01) | -20.89% |
| 3 months (2022-12-28) | -98.33% |
| 6 months (2022-09-26) | -98.29% |
| 1 year (2022-03-25) | N/A |
|---|---|
| 2 years (2021-03-29) | -97.91% |
| 3 years (2020-03-27) | 4.81 |
| 5 years (2018-03-28) | 132 |
| Gross profit TTM | $-42,705,000 |
|---|---|
| Return on assets TTM | -101.08% |
| Return on equity TTM | -202.22% |
| Profit margin | 0% |
| Book value | $0.83 |
| Market capitalisation | $291,915 |
TTM: trailing 12 months
We're not expecting Calithera Biosciences to pay a dividend over the next 12 months.
Calithera Biosciences's shares were split on a 1:20 basis on 14 June 2022. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Calithera Biosciences shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Calithera Biosciences shares which in turn could have impacted Calithera Biosciences's share price.
Over the last 12 months, Calithera Biosciences's shares have ranged in value from as little as $0.041 up to $13.376. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Calithera Biosciences's is 1.2105. This would suggest that Calithera Biosciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Calithera Biosciences, Inc. , a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta.
Here’s what happens to your securities if your brokerage fails, and how your assets are protected by SIPC and FDIC.
Learn about buying physical gold, plus stocks and ETFs, to learn how you can add gold exposure to your portfolio.
Several ETFs have exposure to Silicon Valley Bank, but it appears minimal.
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
The 16th largest US bank has collapsed, but its impact on your portfolio could be limited depending on what you own.
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.